OTC kids’ cough/cold hearing update
This article was originally published in The Tan Sheet
Executive SummaryMembers of the public wishing to register for the public hearing to discuss OTC cough/cold drugs for pediatric use should contact FDA's Faith Dugan directly at 1Faith.Dugan@fda.hhs.gov, rather than go through the 2www.regulations.gov Web site as previously instructed, according to a Federal Register notice slated for publication Sept. 2. FDA provided the updated information about the public hearing to clarify and simplify electronic registration for meeting participants, the agency says
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.